期刊文献+

反应停联合地塞米松治疗多发性骨髓瘤临床观察 被引量:1

Therapeutic effectiveness of thalidomide and dexamethasone to multiple myeloma and its side effects
下载PDF
导出
摘要 目的 观察反应停治疗多发性骨髓瘤 (multiplemyelomaMM)的疗效及不良反应。方法 反应停剂量为15 0 -4 0 0mg d ,地塞米松 2 0 -4 0mg d ,d1-4 ,d9-12 ,d17-2 0。根据M蛋白及骨髓中骨髓瘤细胞的减少情况来判断疗效 ,同时观察血象、肾功能、X线等变化。结果 反应停联合糖皮质激素治疗 9例患者 4例部分缓解 ,2例进步 ,2例无效。总有效率达 66.7%,其中 ,难治性MM有效率达 60 .0 %。大多数患者有轻中度副反应 ,一般能耐受 ,外周血三系大多数无明显下降。 Objective To observe the therapeutic effectiveness and side effects of thalidomide to multiple myeloma. Methods The dosage of thalidomide was 150-400mg/d,dexamethasone was 20-40 mg/d,dl-4,d9-12,d17-20.The therapeutic effectiveness is classified into partial remission,improvement and uneffective, according to the decrease of serum M protein and bone marrow myeloma cells.Peripheral blood counts,renal function and X-rays were also observed.Results The total effective rate was 66.7%. There were no serious side effects.Conclusions Therapy of thalidomide and dexamethasone to multiple myeloma was effective methods and there were no serious side effects.
出处 《海南医学》 CAS 2004年第7期30-31,共2页 Hainan Medical Journal
关键词 反应停 糖皮质激素 多发性骨髓瘤 thalidomide dexamethasone multiple myeloma
  • 相关文献

参考文献3

  • 1Singhal S,Mehta J,Deaikan R,et al.Antitumor activity of thalidomide in refractory multiple myekma.N Engl J Med,1999,341:1565-1571.
  • 2Hideshima T, Chauhan D, Shima Y, et al. th thalidomide and its analogs overcome drug resistance of human myeloma cell to conventional therapy. Blood,2000,96:2943 -2950.
  • 3刘丽辉,武永吉.反应停治疗多发性骨髓瘤的机制及临床应用[J].临床血液学杂志,2002,15(3):138-139. 被引量:31

二级参考文献8

  • 1Bellamy W,List A,Grogan T.Expression of VEGF and its receptors in myeloma.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 2Tosi P,Ronconi S,Zamagni E,et al.Salvage therapy with thalidomide in multiple myeloma patients relapsing after autologous peripheral blood stem cell transplantation[].Haematologica.2001
  • 3Rajkumar S V,Leong T,Roche P C,et al.Prognostic value of bone marrow angiogensis in multiple myeloma[].Clinical Cancer Research.2000
  • 4Schreiber S,Ackermann J,Obermair A,et al.Multiple myeloma with eletion of chromosome 13q is characterized by ineased bone marrow neovascularization[].British Journal of Haematology.2000
  • 5Peuckmann V,Fisch M,Bruera E,et al.Potential novel uses of thalidomide: focus on palliative care[].Drugs.2000
  • 6Celgene.Program and abstracts of the Ⅷinternational myeloma workshop[].Canada Reports.2001
  • 7Faith E D,Noopur R,Teru H,et al.Thalidomide and immunmodulatory derivatives augment natral killer cell cytotoxicity in multiple myeloma[].Blood.2001
  • 8Rajkumar S V,Witzig T E.A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma[].Cancer Treatment Reviews.2000

共引文献30

同被引文献18

  • 1夏俊,陈俊霞,于丽华,崔秀云,陈治文.三氧化二砷抑制小鼠B16黑色素瘤生长作用及其机制[J].中国药理学通报,2004,20(9):1054-1058. 被引量:18
  • 2Jones N, Iljin K, Dumont DJ, et al. Tie receptors: new modulators of angiogenie and lymphangiogenic responses[J]. Nat Rev Mol Cell Biol ,2001,2(4) : 257.
  • 3Aoki Y,Tosato G.Vascular endothelial growth factor/vascnlar permeability factor in the pathogenesis of primary effusion lymphomas[J]. Leuk Lymphoma, 2001,41 (3-4):229.
  • 4Sternlicht M, Werb Z. How matrix metalloproteinases regulate cell behavior[J]. Annu Rev Cell Dev Biol. 2001. 17:463.
  • 5Hamano Y, Zeisberg M, Sugimoto H, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alpha V beta3 intergrin[J]. Cancer Cell, 2003,3(6): 589.
  • 6Coussens LM, Werb Z. Inflammation and cancer. Nature, 2002,420(6917) : 860.
  • 7Scapini P, Lapinet-Vera JA, Gasperini S, et al. The neutrophil as a cellular source of chemokines[J]. Immunol Rev, 2000,177 : 195.
  • 8Beneli R, Morni M, Carrozzino F, et al. Neutrophils as a key cellular terget for angiostain : implications for regulation of angiogenesis and inflammation[J]. FASEB J, 2002, 16(2) : 1371.
  • 9Tosetti F, Ferrari N, de Flora S, et al. Angioprevention : angiogenesis is a common and key target for cancer chemopreventive agents[J]. FASEB J, 2002, 16(1): 2.
  • 10Dell'Aica I, Dona M, Sartor L, et al. (-) Epiallcatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of non-activated MMP-2 at the cell surface[J]. Lab Invest,2002, 82(12) : 1685.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部